CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $16.00 price objective on the stock.

CalciMedica Price Performance

Shares of CALC stock opened at $3.33 on Thursday. The company’s fifty day moving average price is $4.04 and its two-hundred day moving average price is $4.52. The firm has a market capitalization of $44.89 million, a P/E ratio of -3.08 and a beta of 1.30. CalciMedica has a 12 month low of $2.68 and a 12 month high of $8.38.

Insider Activity at CalciMedica

In related news, Director Robert N. Wilson purchased 54,000 shares of CalciMedica stock in a transaction dated Friday, August 23rd. The shares were acquired at an average price of $3.72 per share, with a total value of $200,880.00. Following the completion of the transaction, the director now owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. This trade represents a 17.41 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric W. Roberts acquired 53,333 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, with a total value of $199,998.75. Following the completion of the acquisition, the insider now owns 164,706 shares of the company’s stock, valued at $617,647.50. The trade was a 47.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 312,944 shares of company stock valued at $1,172,910. Insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Geode Capital Management LLC lifted its holdings in CalciMedica, Inc. (NASDAQ:CALC) by 51.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 66,553 shares of the company’s stock after buying an additional 22,525 shares during the quarter. Geode Capital Management LLC owned approximately 0.62% of CalciMedica worth $295,000 as of its most recent filing with the SEC.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.